Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111445 · ClinicalTrials.gov registry record · Phase 1
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Adagene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04111445 is a Phase 1 study that was terminated before completion, run by Adagene. The registered enrollment target is 1 participants.
The verdict
NCT04111445, a Phase 1 study, was terminated before completion, sponsored by Adagene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes. The study planned to treated 42 patients.
Interventions
- DRUG ADG116
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2021-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111445
The ClinicalTrials.gov registry entry for NCT04111445 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adagene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADG116 is the first listed.
NCT04111445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04111445 about?
NCT04111445 is a clinical study titled "Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors". This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes...
What is the current status of trial NCT04111445?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2019-08-29. Estimated completion is 2021-04-27.
What interventions are being tested in trial NCT04111445?
The interventions under investigation include: ADG116 (DRUG).
Who is sponsoring clinical trial NCT04111445?
This trial is sponsored by Adagene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.